Venetoclax helps restore the process of apoptosis in newly diagnosed AML with the first and only BCL-2 inhibitor 1

Suppression of the apoptotic pathway is a key mechanism for the survival and proliferation of hematologic cancer cells. 10

  • Overexpressed BCL-2 allows hematologic cancer cells to evade apoptosis by sequestering pro-apoptotic proteins 1
  • Venetoclax selectively binds to BCL-2, displacing pro-apoptotic proteins, and triggering events that lead to apoptosis 1

BCL-2 is expressed in the majority of patients with AML 11-13

  • Approximately 80% of patients with AML overexpress a BCL-2 pro-survival protein 14
  • In non-clinical studies, VENCLEXTA has demonstrated cytotoxic activity in tumor cells that overexpress BCL-2 1
  • Initiation of VENCLEXTA in patients with AML does not require biomarker or cytogenetic testing results 1

MOA=mechanism of action; AML=acute myeloid leukemia; BCL-2=B cell lymphoma 2.